Search


Current filters:
Start a new search
Add filters:

Use filters to refine the search results.


Results 71-80 of 184 (Search time: 0.003 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2009Dasatinib inhibits the secretion of TNF-α following TLR stimulation in vitro and in vivoFraser, C.; Lousberg, E.; Kumar, R.; Hughes, T.; Diener, K.; Hayball, J.
2013STAT5 is a critical component of the time-dependent sensitivity of CML cells to TKI treatment in a BCR-ABL-dependent, but JAK2-independent mannerSchafranek, L.; Nievergall, E.; Powell, J.; Hiwase, D.; White, D.; Hughes, T.; Leclercq, T.
2009Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivoFraser, C.; Blake, S.; Diener, K.; Lyons, A.; Brown, M.; Hughes, T.; Hayball, J.
2013Dasatinib targets chronic myeloid leukemia-CD34⁺ progenitors as effectively as it targets mature cellsHiwase, D.; Saunders, V.; Nievergall, E.; Ross, D.; White, D.; Hughes, T.
2010Dasatinib alters the metastatic phenotype of B16-OVA melanoma in vivoFraser, C.; Lousberg, E.; Guerin, L.; Hughes, T.; Brown, M.; Diener, K.; Hayball, J.
2012Drug-interaction studies evaluating T-cell proliferation reveal distinct activity of dasatinib and imatinib in combination with cyclosporine ABlake, S.; Hughes, T.; Lyons, A.
2000Normal and leukemic engraftment in the nod/scid mouse modelHughes, T.; White, D.; Bresatz, S.; Forte, M.; Lewis, I.; Lyons, A.
2008Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implicationsHiwase, D.; Saunders, V.; Hewett, D.; Frede, A.; Zrim, S.; Dang, P.; Eadie, L.; To, L.; Vaz de Melo, J.; Kumar, S.; Hughes, T.; White, D.
2010Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitorsHiwase, D.; White, D.; Powell, J.; Saunders, V.; Zrim, S.; Frede, A.; Guthridge, M.; Lopez, A.; D'Andrea, R.; To, L.; Vaz de Melo, J.; Kumar, S.; Hughes, T.
2010Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapyHiwase, D.; White, D.; Zrim, S.; Saunders, V.; Vaz de Melo, J.; Hughes, T.